Cargando…
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors
AIMS: To assess prognostic value of pre-therapy carcinoembryonic antigen (CEA) and cytokeratin-19 fragments (CYFRA 21-1) blood levels in non-small cell lung cancer (NSCLC) patients treated with immune-checkpoint inhibitors (ICIs) and their early change as predictor of benefit. MATERIALS AND METHODS:...
Autores principales: | Dall’Olio, Filippo G., Abbati, Francesca, Facchinetti, Francesco, Massucci, Maria, Melotti, Barbara, Squadrilli, Anna, Buti, Sebastiano, Formica, Francesca, Tiseo, Marcello, Ardizzoni, Andrea |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607728/ https://www.ncbi.nlm.nih.gov/pubmed/33193825 http://dx.doi.org/10.1177/1758835920952994 |
Ejemplares similares
-
Monitoring tumor growth rate to predict immune checkpoint inhibitors’ treatment outcome in advanced NSCLC
por: Dall’Olio, Filippo G., et al.
Publicado: (2022) -
High Serum CEA and CYFRA21-1 Levels after a Two-Cycle Adjuvant Chemotherapy for NSCLC: Possible Poor Prognostic Factors
por: Lin, Xue-feng, et al.
Publicado: (2012) -
The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients
por: Dal Bello, M. G., et al.
Publicado: (2019) -
Prognostic value of serum CYFRA21-1 and CEA for non-small-cell lung cancer
por: Zhang, Zhi-Hui, et al.
Publicado: (2015) -
Postoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I pulmonary adenocarcinoma
por: He, Ying, et al.
Publicado: (2017)